Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Kim ST, Lim DH, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO.
Kim ST, et al. Among authors: lim dh, lim hy, lim t.
Mol Cancer Ther. 2011 Oct;10(10):1993-9. doi: 10.1158/1535-7163.MCT-11-0269. Epub 2011 Aug 23.
Mol Cancer Ther. 2011.
PMID: 21862683
Clinical Trial.